Trial · NCT01360840
Results by group65
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 65
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) Time | Placebo + SoC | 3.3 | 95% Confidence Interval 2.8 to 4.8 | months | |
| Progression Free Survival (PFS) Time | EMD 525797 750 mg + SoC | 3.4 | 95% Confidence Interval 2.8 to 5.6 | months | |
| Progression Free Survival (PFS) Time | EMD 525797 1500 mg + SoC | 4.3 | 95% Confidence Interval 2.8 to 6.6 | months | |
| Overall Survival | Placebo + SoC | NA | 95% Confidence Interval 14.8 to NA | months | |
| Overall Survival | EMD 525797 750 mg + SoC | NA | 95% Confidence Interval 12.9 to NA | months | |
| Overall Survival | EMD 525797 1500 mg + SoC | NA | 95% Confidence Interval 14.4 to NA | months | |
| Time to Tumor Progression | Placebo + SoC | 3.3 | 95% Confidence Interval 2.8 to 5.4 | months | |
| Time to Tumor Progression | EMD 525797 750 mg + SoC | 3.4 | 95% Confidence Interval 2.8 to 5.6 | months | |
| Time to Tumor Progression | EMD 525797 1500 mg + SoC | 4.6 | 95% Confidence Interval 2.8 to 6.9 | months | |
| Number of Subjects With Presence of Tumor Response and Disease Control (DC) in Soft Tissue Lesions | Placebo + SoC | Tumor response | 1 | Subjects | |
| Number of Subjects With Presence of Tumor Response and Disease Control (DC) in Soft Tissue Lesions | EMD 525797 750 mg + SoC | Tumor response | 0 | Subjects | |
| Number of Subjects With Presence of Tumor Response and Disease Control (DC) in Soft Tissue Lesions | EMD 525797 1500 mg + SoC | Tumor response | 1 | Subjects | |
| Number of Subjects With Presence of Tumor Response and Disease Control (DC) in Soft Tissue Lesions | Placebo + SoC | Disease control | 2 | Subjects | |
| Number of Subjects With Presence of Tumor Response and Disease Control (DC) in Soft Tissue Lesions | EMD 525797 750 mg + SoC | Disease control | 3 | Subjects | |
| Number of Subjects With Presence of Tumor Response and Disease Control (DC) in Soft Tissue Lesions | EMD 525797 1500 mg + SoC | Disease control | 4 | Subjects | |
| Number of Subjects With New Bone Lesions Compared to Baseline | Placebo + SoC | 40 | Subjects | ||
| Number of Subjects With New Bone Lesions Compared to Baseline | EMD 525797 750 mg + SoC | 34 | Subjects | ||
| Number of Subjects With New Bone Lesions Compared to Baseline | EMD 525797 1500 mg + SoC | 34 | Subjects | ||
| Number of Subjects With Presence of DC in Bone Lesions | Placebo + SoC | Week 13 | 4 | Subjects | |
| Number of Subjects With Presence of DC in Bone Lesions | EMD 525797 750 mg + SoC | Week 13 | 7 | Subjects |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01360840/results